Singapore markets open in 51 minutes
Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,187.67 -0.03 (-0.00%) Dow
39,056.39 +172.13 (+0.44%) Nasdaq
16,302.76 -29.80 (-0.18%) Bitcoin USD
61,190.32 -1,208.51 (-1.94%) CMC Crypto 200
1,303.79 +9.12 (+0.70%)
Eli Lilly and Company (LILY34.SA)
São Paulo - São Paulo Delayed price. Currency in BRL
Add to watchlist
At close: 05:10PM BRT
| Previous close | 131.56 |
| Open | 131.83 |
| Bid | 131.50 x 0 |
| Ask | 132.93 x 0 |
| Day's range | 131.06 - 132.93 |
| 52-week range | 69.45 - 137.15 |
| Volume | |
| Avg. volume | 13,833 |
| Market cap | 3.776T |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 116.10 |
| EPS (TTM) | 1.14 |
| Earnings date | 08 Aug 2024 |
| Forward dividend & yield | 0.60 (0.46%) |
| Ex-dividend date | 14 Feb 2024 |
| 1y target est | N/A |
ZacksAre You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BenzingaWhat About Eli Lilly's Drug For Early Alzheimer's? FDA Panel To Discuss Next Month
Tuesday, the FDA said it would convene an in-person meeting of the Peripheral and Central Nervous System Drugs Advisory Committee on Monday, June 10, 2024, to discuss Eli Lilly and Co’s (NYSE:LLY) donanemab for early symptomatic Alzheimer’s disease. The open public hearing portion of the meeting will be conducted virtually. The Phase 3 study submitted as part of this application, TRAILBLAZER-ALZ 2, is a double-blind, placebo-controlled study to evaluate the safety and efficacy of donanemab in pa
ZacksA Look at Pharma ETFs Post Q1 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
© 2024 Yahoo. All rights reserved.